Physician profile
Gregory J Kramer
NPI 1598793283
$12,036.67
in general payments reported to CMS, 2019-2025
19 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 83% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $1,331 · 2021: $7,849 · 2022: $1,069 · 2023: $73.35 · 2024: $168 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766 · Travel and Lodging: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $765.69 |
| Travel and Lodging | $690.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intelivation Technologies, LLC | $8,500.00 | 2021-2022 | |
| Acelrx Pharmaceuticals, INC. | $1,200.00 | 2020 | |
| Cgg Medical INC | $660.49 | 2025 | |
| Arthrex, INC. | $452.20 | 2025 | |
| Organogenesis INC. | $282.54 | 2019-2021 | |
| Smith+Nephew, INC. | $272.01 | 2019-2025 | Collagenase Santyl, Regranex |
| Zimmer Biomet Holdings, INC. | $134.48 | 2021 | |
| Crossroads Extremity Systems, LLC | $108.11 | 2019 | |
| Treace Medical Concepts, INC. | $100.89 | 2024 | |
| Paragon 28, INC. | $94.21 | 2021 | |
| Biocomposites INC | $41.88 | 2025 | Stimulan |
| Kerecis Limited | $32.24 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $28.12 | 2022 | |
| Amgen INC. | $27.14 | 2025 | Krystexxa |
| Medela LLC | $26.62 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.15 | 2021 | |
| Davol INC. | $19.63 | 2021 | |
| Mimedx Group, INC. | $16.34 | 2024 | |
| Integra Lifesciences Corporation | $15.62 | 2023 | Tenoglide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.